New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension: A Systematic Review and Meta-Analysis

被引：4
|
作者：
Mahfooz, Kamran [1 ]
Najeed, Syed [2 ]
Tun, Han Naung [3 ]
Khamosh, Madina [4 ]
Grewal, Daisy [4 ]
Hussain, Aftab
Ong, Kenneth [1 ]
Dharmarajan, Lekshmi [1 ]
Vasavada, Advait [5 ,6 ,7 ]
机构：
[1] Lincoln Med Ctr, New York, NY USA
[2] Wright State Univ, Boonshoft Sch Med, Dept Med, Div Cardiol, Dayton, OH 45435 USA
[3] Larner Coll Med Univ Vermont, Cardiol Dept, Burlington, VT USA
[4] St Georges Univ, St Georges, Grenada
[5] Paras HMRI Hosp, Patna, India
[6] MP Shah Med Coll, Jamnagar, India
[7] MP Shah Med Coll, 2 Green Pk Apartment,Pk Colony, Jamnagar 361008, India
来源：
CURRENT PROBLEMS IN CARDIOLOGY | 2023年 / 48卷 / 07期
关键词：
PHARMACOKINETICS; ALDOSTERONE; AVOSENTAN; BLOCKADE; SAFETY; ET(A);
D O I：
10.1016/j.cpcardiol.2023.101686
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Hypertension is one of the most common disorders encountered, yet pharmacotherapy for resis-tant hypertension has limited effective options. Aproci-tentan is postulated to be a novel antihypertensive. The main goal was to determine the effect of aprocitentan on blood pressure among patients with hypertension. A thorough search of 5 electronic databases, including PubMed Central, PubMed, EMBASE, Springer, and Google Scholar, was carried out. The study included eight articles. With doses exceeding 25 mg, plasma ET-1(endothelin-1) concentrations, which show ETB (Endothelin receptor type B) receptor antagonism, sig-nificantly rose. Aprocitentan significantly reduced sys-tolic and diastolic blood pressure with both doses of 10mg and 25mg in patients with hypertension. Further research is warranted to evaluate the efficacy, safety, and long-term outcomes of aprocitentan and its syner-gistic effect with other antihypertensives. (Curr Probl Cardiol 2023;48:101686.)
引用
收藏
页数：16
相关论文
共 50 条
  • [1] Safety and efficacy of new dual endothelin receptor antagonist aprocitentan in resistant hypertension: a systematic review and meta-analysis
    Azmi, Yusuf
    Widyantoro, Bambang
    [J]. CLINICAL SCIENCE, 2024, 138
  • [2] Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension
    Verweij, Pierre
    Danaietash, Parisa
    Flamion, Bruno
    Menard, Joel
    Bellet, Marc
    [J]. HYPERTENSION, 2020, 75 (04) : 956 - 965
  • [3] Efficacy and safety of various doses of the new dual endothelin receptor antagonist aprocitentan in the treatment of hypertension
    Danaietash, P.
    Verweij, P.
    Flamion, B.
    Menard, J.
    Bellet, M.
    [J]. EUROPEAN HEART JOURNAL, 2019, 40 : 6 - 6
  • [4] Aprocitentan (a Dual Endothelin-Receptor Antagonist) for Treatment-Resistant Hypertension
    McCoy, Emily K.
    Lisenby, Katelin M.
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2021, 77 (06) : 699 - 766
  • [5] Aprocitentan Dual endothelin ETA/ETB receptor antagonist Treatment of resistant hypertension
    Warden, B. A.
    Duell, P. B.
    [J]. DRUGS OF THE FUTURE, 2021, 46 (08) : 595 - 611
  • [6] Aprocitentan, A Dual Endothelin Receptor Antagonist Under Development for the Treatment of Resistant Hypertension
    Angeli, Fabio
    Verdecchia, Paolo
    Reboldi, Gianpaolo
    [J]. CARDIOLOGY AND THERAPY, 2021, 10 (02) : 397 - 406
  • [7] Aprocitentan, A Dual Endothelin Receptor Antagonist Under Development for the Treatment of Resistant Hypertension
    Fabio Angeli
    Paolo Verdecchia
    Gianpaolo Reboldi
    [J]. Cardiology and Therapy, 2021, 10 : 397 - 406
  • [8] Population pharmacokinetics of the dual endothelin receptor antagonist aprocitentan in subjects with or without essential or resistant hypertension
    Brussee, Janneke M.
    Sidharta, Patricia N.
    Dingemanse, Jasper
    Krause, Andreas
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2024, 51 (03) : 243 - 252
  • [9] The efficiency of endothelin receptor antagonist bosentan for pulmonary arterial hypertension associated with congenital heart disease: A systematic review and meta-analysis
    Kuang, Hong-Yu
    Wu, Yu-Hao
    Yi, Qi-Jian
    Tian, Jie
    Wu, Chun
    Shou, We Nian
    Lu, Tie-Wei
    [J]. MEDICINE, 2018, 97 (10)
  • [10] Absorption, Distribution, Metabolism, and Excretion of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Humans
    Sidharta, Patricia N.
    Fischer, Hartmut
    Dingemanse, Jasper
    [J]. CURRENT DRUG METABOLISM, 2021, 22 (05) : 399 - 410
12345